Genitourinary Medical Oncology Clinic

Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer

The Decisional Conflict Scale measures personal perceptions of : a) uncertainty in choosing options; b) modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in de...

Recruiting

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combina...

Objective response rate, defined as the proportion of participants with a CR or PR on two consecutive occasions >=4 weeks apart during Stage 1, as determined by the investigator according to RECIST v1.1.

Recruiting

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostat...

A minimum of 3 patients will be treated at each dose level. If < 33%of patients (i.e. 0 of 3 patients, or 1 of 6 patients) within a cohort have a dose-limiting toxicity (DLT in Cycle 1, then enrollment of the next cohort may comme...

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation ...

Adverse events, serious adverse events, and dose limiting toxicities

Recruiting

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prost...

The composite response rate is determined by a combination of a decline from baseline in serum PSA of >= 50%, confirmed by repeat measurement ≥ 4 weeks later (PSA50) AND/OR a complete response (CR) or partial response (PR) as dete...

Recruiting

Predicting Cognitive Decline From Androgen Deprivation Therapy

Proportion with cognitive decline, defined as a decrease in >=1 neurocognitive test after ADT by >=1 standard deviation (SD) compared to baseline.

Recruiting

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocy...

Treatment-related adverse events as assessed by CTCAE v4.0

Recruiting

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant ...

Defined as either objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (complete response (CR), partial response (PR)) or confirmed >= 50% decline from serum prostate-specific antigen (PSA) at ...

Recruiting

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With So...

On overall response will be reported as a percentage of participants with a complete response (CR) or partial response (PR) as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

Recruiting

Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With C...

The primary endpoint for the study is the proportion of patients with undetectable serum PSA (< 0.2 ng/mL) at 6 months following completion of apalutamide therapy (18 months from date of randomization). Patients who discontinue ap...

Recruiting